KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Current Deferred Revenue (2016 - 2017)

Supernus Pharmaceuticals (SUPN) has disclosed Current Deferred Revenue for 7 consecutive years, with $287000.0 as the latest value for Q4 2017.

  • Quarterly Current Deferred Revenue rose 37.32% to $287000.0 in Q4 2017 from the year-ago period, while the trailing twelve-month figure was $287000.0 through Dec 2017, up 37.32% year-over-year, with the annual reading at $287000.0 for FY2017, 37.32% up from the prior year.
  • Current Deferred Revenue for Q4 2017 was $287000.0 at Supernus Pharmaceuticals, roughly flat from $287000.0 in the prior quarter.
  • The five-year high for Current Deferred Revenue was $417000.0 in Q1 2013, with the low at $143000.0 in Q2 2014.
  • Average Current Deferred Revenue over 5 years is $218350.0, with a median of $207500.0 recorded in 2016.
  • Peak annual rise in Current Deferred Revenue hit 79.74% in 2013, while the deepest fall reached 59.84% in 2013.
  • Over 5 years, Current Deferred Revenue stood at $204000.0 in 2013, then decreased by 29.9% to $143000.0 in 2014, then rose by 23.08% to $176000.0 in 2015, then grew by 18.75% to $209000.0 in 2016, then surged by 37.32% to $287000.0 in 2017.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $287000.0, $287000.0, and $287000.0 for Q4 2017, Q3 2017, and Q2 2017 respectively.